Core Viewpoint - The traditional Chinese medicine sector experienced a slight decline of 0.12% on December 26, with ST Bailin leading the drop, while the overall Shanghai Composite Index rose by 0.1% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3963.68, up 0.1% [1]. - The Shenzhen Component Index closed at 13603.89, up 0.54% [1]. - The traditional Chinese medicine sector saw a net outflow of 229 million yuan from major funds, while retail investors contributed a net inflow of 195 million yuan [2][3]. Group 2: Individual Stock Performance - Notable gainers included: - Zhongsheng Pharmaceutical (002317) with a closing price of 20.06, up 2.92% [1]. - Wanbangde (002082) closed at 13.70, up 2.09% [1]. - Tongrentang (600085) closed at 32.25, up 1.26% [1]. - Major decliners included: - ST Bailin (002424) closed at 4.59, down 4.97% [2]. - *ST Changyao (300391) closed at 1.47, down 3.92% [2]. - Jinhua Co. (600080) closed at 7.76, down 2.51% [2]. Group 3: Trading Volume and Capital Flow - Zhongsheng Pharmaceutical had a trading volume of 747,200 shares and a transaction value of 149 million yuan [1]. - ST Bailin had a trading volume of 849,300 shares with a transaction value of 391 million yuan [2]. - The capital flow data indicates that major funds had a net inflow in Zhongsheng Pharmaceutical, while other stocks like Tongrentang and Wanbangde saw mixed capital flows [3].

证券日报网讯 12月23日，特一药业发布公告称，公司第六届董事会第五次会议审议通过《关于部分募 投项目延期的议案》。 （文章来源：证券日报） ...

每经AI快讯，特一药业（SZ 002728，收盘价：11.24元）12月23日晚间发布公告称，公司第六届第五次 董事会会议于2025年12月23日在公司会议室采用现场及电子通信方式召开。会议审议了《关于部分募投 项目延期的议案》等文件。 2025年1至6月份，特一药业的营业收入构成为：医药工业占比98.52%，医药商业占比0.87%，化工产品 及其他占比0.61%。 截至发稿，特一药业市值为58亿元。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 （记者 曾健辉） ...

南财智讯12月23日电，特一药业公告，公司拟将"药品仓储物流中心及信息系统建设项目"达到预定可使 用状态日期由2025年12月31日延期至2026年12月31日。该项目变更后拟投入募集资金13606.33万元，资 金来源为公开发行可转换公司债券募集资金，用于药品仓储物流体系及信息系统的建设。延期原因为部 分实施地点变更至台山市水步镇振兴路21号，受该宗地整体规划与设计进度影响，项目建设仍在进行 中。公司基于审慎性原则，为保障项目质量而作出延期决定。本次延期不涉及项目实施主体、用途、投 资规模的变更，不影响募集资金的投向，不存在改变或变相改变募集资金用途的情形，不会对公司主营 业务和财务状况产生重大不利影响，整体募资安排保持不变。 ...

东莞证券股份有限公司 关于特一药业集团股份有限公司公开发行可转换公司债券 募集资金投资项目延期的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023 年以简易程序向特定对象 发行股票并上市的保荐机构，承接了特一药业公开发行可转换公司债券的保荐机构国 信证券股份有限公司未完成的持续督导职责。根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规定，对特一药业公 开发行可转换公司债券募集资金投资项目延期的事项进行了审慎核查，核查情况及意 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2017]2004 号文《关于核准特一药业集团股 份有限公司公开发行可转换公司债券的批复》核准，公司获准于 2017 年 12 月 6 日向 社 会 公 开 发 行 3,540,000 张 可 转 换 公 司 债 券 ， 每 张 面 值 100 元 ， 发 行 总 额 354,000,000.00 元。 公司发行可转 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-066 经中国证券监督管理委员会证监许可[2017]2004 号文《关于核准特一药业集团股份 有限公司公开发行可转换公司债券的批复》核准，公司获准于 2017 年 12 月 6 日向社会 公开发行 3,540,000 张可转换公司债券，每张面值 100 元，发行总额 354,000,000.00 元。 公司发行可转债募集资金总额为人民币 354,000,000.00 元，利息为 12,776.67 元， 扣除承销费用、保荐费人民币 6,000,000.00 元后的发行金额 348,012,776.67 元，已由 保荐人（主承销商）于 2017 年 12 月 12 日汇入本公司募集资金专项存储账户内。另扣 除律师、会计师、资信评级、信息披露费及发行手续费等其他发行费用合计 1,655,400.00 元，实际募集资金净额为 346,357,376.67 元。该项募集资金到位情况业经瑞华会计师 事务所（特殊普通合伙）验证并出具瑞华验字[2017]48470002 号验证报告。公司依照规 定对募集资金进行了专户存储管理，募集资金到账后已全部存放于募集资金 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-065 关于第六届董事会第五次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。） 特此公告。 特一药业集团股份有限公司 一、董事会会议召开情况 特一药业集团股份有限公司（以下简称"公司"）第六届董事会第五次会议于 2025 年 12 月 23 日 10:15 在公司会议室采用现场及电子通信方式召开，会议通知于 2025 年 12 月 13 日以电子邮件方式发出。本次会议由董事长许荣煌主持，应出席董事 6 名，实 际出席 6 名，其中卢北京、赵晓波、赖瀚琪等 3 名董事以电子通信表决方式出席会议。 公司非董事高级管理人员列席了本次会议。会议的召集、召开符合《公司法》和《公司 章程》的相关规定。 二、董事会会议审议情况 1、审议通过《关于部分募投项目延期的议案》 详见同日刊登在巨潮资讯网上的《关于部分募投项目延期的公告》。 特一药业集团股份有限公司 董事会 2025 年 12 月 24 日 ...

Core Viewpoint - The stock of Te Yi Pharmaceutical experienced a decline of 2.15% on December 23, with a current price of 10.93 CNY per share and a market capitalization of 5.607 billion CNY. The company has shown a year-to-date stock price increase of 22.80% but has faced recent declines in the short term [1]. Financial Performance - For the period from January to September 2025, Te Yi Pharmaceutical achieved a revenue of 692 million CNY, representing a year-on-year growth of 51.86%. The net profit attributable to shareholders was 65.217 million CNY, showing a significant increase of 985.18% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical was 58,100, an increase of 10.11% from the previous period. The average number of tradable shares per shareholder decreased by 9.09% to 6,481 shares [2]. Dividend Distribution - Te Yi Pharmaceutical has distributed a total of 1.059 billion CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, the third-largest shareholder is the Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A, holding 3.3338 million shares. The fourth-largest is the Xingquan Hu-Shen 300 Index Enhanced (LOF) A, holding 1.9202 million shares, both of which have not changed in quantity compared to the previous period. The Hong Kong Central Clearing Limited, ranked ninth, reduced its holdings by 7.4217 million shares to 1.3696 million shares [3].

Core Viewpoint - The company is committed to dual-track research in traditional Chinese medicine (TCM) and chemical drugs, aiming to enhance product quality and market competitiveness through innovation [1] Group 1: Traditional Chinese Medicine (TCM) Development - The company is focusing on the inheritance and development of existing TCM products, conducting clinical and real-world studies for secondary development of key TCM products such as cough tablets, skin disease blood detox pills, and blood sugar-lowering pills [1] - The goal is to grow these TCM products into major categories, enhancing the "Te Yi" brand influence and market competitiveness [1] - The company is actively seizing opportunities in the TCM industry by strengthening collaborations with relevant research institutions to develop innovative TCM drugs [1] Group 2: Chemical Drug Development - The company is conducting integrated innovation research on "active pharmaceutical ingredients + formulations," focusing on cutting-edge research for drugs treating major diseases [1] - The approach involves a synergistic model of developing both formulations and active pharmaceutical ingredients to enhance overall research efficiency [1]

Group 1 - The core viewpoint of the article highlights the positive impact of Hainan's free trade port policies on the biopharmaceutical industry, particularly for Teva Pharmaceutical [2] - The company acknowledges the implementation of supportive policies covering the entire chain of research, innovation, production, and industrial upgrading in Hainan [2] - Teva Pharmaceutical and its subsidiary, Hainan Haili Pharmaceutical, are actively studying the specific policies that will be implemented post the full closure of Hainan, aiming to integrate these opportunities with their existing business and future plans [2] Group 2 - The company expresses its commitment to contributing to the local biopharmaceutical industry's development and participating in Hainan's economic construction [2] - Teva Pharmaceutical assures that it will comply with regulatory requirements and fulfill information disclosure obligations regarding any specific development plans in the future [2]